Balyasny Asset Management LLC Lyell Immunopharma, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
A detailed history of Balyasny Asset Management LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 985,336 shares of LYEL stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
985,336
Previous 236,754
316.19%
Holding current value
$1.26 Million
Previous $527,000
170.97%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LYEL
# of Institutions
123Shares Held
145MCall Options Held
2.6KPut Options Held
7.5K-
Mwg Management Ltd. Washington, DC20.2MShares$25.8 Million31.93% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$19.3 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$19.3 Million16.63% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$17.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$17.1 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $317M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...